Your statement of device sales to new patients is a dead end revenue is at odds with the quarterly update results showing:for every $ of new device revenue there is 95.2% of revenue for total masks & other with SAAS. And RMD is managing to increase this % from 83.6% to 95.2%
The concerns about margin decrease is grossly overblown for a very healthy margin of 56%. Instead of highlighting gross profit increased by 10.96% from $540.81m to $600.06m the Naysayers highlighted the nominal margin decrease. How do you increase production with existing resources? Overtime & shift works will increase the average unit production costs.? Are the Naysayers saying RMD should not increase revenue for a norminal decrease of 2.5% margin from 56.9% to 54.4%?
RMD Price at posting:
$23.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)